Therefore, patients also receiving an insulin secretagogue (e.g., sulfonylurea, meglitinide) may require a lower dose of the insulin secretagogue to reduce the risk of hypoglycemia [see Dosage and Administration]
Tian J, Venn A, Otahal P, Gall S
We simply do not have a robust human safety database comparable to what would be required for a pharmaceutical product undergoing regulatory review
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
In addition, oral glutathione supplements have been linked to digestive distress, including abdominal cramps or bloating
Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study